These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 6385429)

  • 21. [Type of isoniazid (INH) acetylation determined in tuberculosis patients treated at the Institute of Tuberculosis and Lung Diseases in Warsaw during the years 1990-1997].
    Augustynowicz-Kopeć E; Zwolska Z
    Pneumonol Alergol Pol; 2002; 70(3-4):180-92. PubMed ID: 12271965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population screening for isoniazid acetylator phenotype.
    Seifart HI; Parkin DP; Botha FJ; Donald PR; Van Der Walt BJ
    Pharmacoepidemiol Drug Saf; 2001; 10(2):127-34. PubMed ID: 11499851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors for hepatotoxicity during anti-tuberculosis chemotherapy in Asian populations.
    Yew WW
    Int J Tuberc Lung Dis; 2001 Jan; 5(1):99-100. PubMed ID: 11263525
    [No Abstract]   [Full Text] [Related]  

  • 24. Acetylator phenotype key to INH side effects.
    Forester D
    Ann Emerg Med; 1980 Mar; 9(3):173. PubMed ID: 7362111
    [No Abstract]   [Full Text] [Related]  

  • 25. Liver damage and isoniazid allergy.
    Assem ES; Ndoping N; Nicholson H; Wade JR
    Clin Exp Immunol; 1969 Oct; 5(4):439-42. PubMed ID: 5359962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Levels of acetyl hydrazines and rate of acetylation of isoniazid in adult tuberculosis patients.
    Bhalerao EB; Bhide SV
    Indian J Physiol Pharmacol; 1985; 29(2):83-8. PubMed ID: 4093196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Phenotype of isoniazid acetylation and tolerance of antitubercular drugs].
    Gontsa FT; Savina LA; Tsurkan VP; Kovalenko IP
    Probl Tuberk; 1988; (2):35-8. PubMed ID: 3375215
    [No Abstract]   [Full Text] [Related]  

  • 28. [Incidence of hepatotoxic side effects during antituberculous therapy (INH, RMP, EMB) in relation to the acetylator phenotype (author's transl)].
    Musch E; Eichelbaum M; Wang JK; von Sassen W; Castro-Parra M; Dengler HJ
    Klin Wochenschr; 1982 May; 60(10):513-9. PubMed ID: 7098379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Twice-weekly streptomycin plus isoniazid for tuberculosis.
    Stradling P; Poole GW
    Tubercle; 1970 Mar; 51(1):44-7. PubMed ID: 5495335
    [No Abstract]   [Full Text] [Related]  

  • 30. Simplified isoniazid acetylator phenotyping.
    Russell DW; Eidus L
    Can Med Assoc J; 1972 Jun; 106(11):1155-6. PubMed ID: 5034694
    [No Abstract]   [Full Text] [Related]  

  • 31. Isoniazid acetylation rates (phenotypes) of patients being treated for tuberculosis.
    Mason E; Russell DW
    Bull World Health Organ; 1971; 45(5):617-24. PubMed ID: 5316954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acetylator phenotyping of tuberculosis patients using matrix isoniazid or sulphadimidine and its prognostic significance for treatment with several intermittent isoniazid-containing regimens.
    Ellard GA; Gammon PT
    Br J Clin Pharmacol; 1977 Feb; 4(1):5-14. PubMed ID: 843424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors for isoniazid (NIH)-induced liver dysfunction.
    Dickinson DS; Bailey WC; Hirschowitz BI; Soong SJ; Eidus L; Hodgkin MM
    J Clin Gastroenterol; 1981 Sep; 3(3):271-9. PubMed ID: 7288121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis.
    Mitchell JR; Zimmerman HJ; Ishak KG; Thorgeirsson UP; Timbrell JA; Snodgrass WR; Nelson SD
    Ann Intern Med; 1976 Feb; 84(2):181-92. PubMed ID: 766682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Importance of acetylation and oxidation in inactivation of isonicotinic acid hydrazide preparations.
    Smirnov GA
    Fed Proc Transl Suppl; 1966; 25(1):72-6. PubMed ID: 5322111
    [No Abstract]   [Full Text] [Related]  

  • 36. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis.
    Parkin DP; Vandenplas S; Botha FJ; Vandenplas ML; Seifart HI; van Helden PD; van der Walt BJ; Donald PR; van Jaarsveld PP
    Am J Respir Crit Care Med; 1997 May; 155(5):1717-22. PubMed ID: 9154882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatic function in relation to acetylator phenotype in children treated with antitubercular drugs.
    Seth V; Beotra A
    Indian J Med Res; 1989 Sep; 89():306-9. PubMed ID: 2628292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isoniazid phenotyping in Munda and Oraon tribes of Chhotanagpur division suffering from pulmonary tuberculosis by sulphadimidine acetylation test.
    Sinha CP; Sinha S; Sinha KP; Choudhary KD
    Indian J Med Sci; 1980 Aug; 34(8):189-92. PubMed ID: 7203584
    [No Abstract]   [Full Text] [Related]  

  • 39. Complete sequencing of a genetic polymorphism in NAT2 in the Korean population.
    Lee SY; Lee KA; Ki CS; Kwon OJ; Kim HJ; Chung MP; Suh GY; Kim JW
    Clin Chem; 2002 May; 48(5):775-7. PubMed ID: 11978608
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of two pulmonary tuberculosis drug treatments and acetylator status on liver function in a Zimbabwean population.
    Neill P; Pringle D; Mhonda M; Kusema T; Nhachi CF
    Cent Afr J Med; 1990 Apr; 36(4):104-7. PubMed ID: 2225025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.